[Intraductal neoplasms of the pancreas].

Intraduktale Pankreasneoplasien.

Journal

Der Pathologe
ISSN: 1432-1963
Titre abrégé: Pathologe
Pays: Germany
ID NLM: 8006541

Informations de publication

Date de publication:
Sep 2021
Historique:
accepted: 30 06 2021
pubmed: 18 8 2021
medline: 1 9 2021
entrez: 17 8 2021
Statut: ppublish

Résumé

The latest WHO classification of tumors of the digestive system (2019) has introduced new concepts for the stratification of intraductal neoplasms of the pancreas, mostly based on molecular genetics and malignant potential. Among them, pancreatic intraepithelial neoplasias (PanINs) and intraductal papillary mucinous neoplasms (IPMN) are both precursors of pancreatic ductal adenocarcinoma, whereas intraductal oncocytic papillary neoplasms (IOPN) and intraductal tubulopapillary neoplasms (ITPN) are usually associated with less aggressive subtypes of pancreatic cancer and therefore have a much better prognosis. Hence, it is of utmost importance to correctly classify these lesions and to distinguish them from each other as well as from other nonductal types of neoplasms, which can rarely display an intraductal growth, such as neuroendocrine tumors and acinar cell carcinomas. PanIN are microscopic lesions with limited clinical significance. In contrast, all other intraductal neoplasms can be identified as cystic processes and/or solid tumors by means of imaging, thereby setting an indication for a potential surgical resection. This review presents diagnostically relevant aspects of intraductal neoplasms of the pancreas, which are instrumental for the discussion within interdisciplinary tumor boards (resection vs. watch-and-wait strategies) as well as to determine the extent of resection intraoperatively. Die aktuelle WHO-Klassifikation für gastrointestinale Tumoren (2019) beinhaltet Neuerungen in der Einteilung von intraduktalen Pankreasneoplasien, die auf weiterführenden Erkenntnissen zum genetischen Profil der Tumoren und zum Malignitätspotenzial basieren. Zu dieser Gruppe zählen pankreatische intraepitheliale Neoplasien (PanIN) und intraduktale papillär-muzinöse Neoplasien (IPMN) als Vorläufer des duktalen Adenokarzinoms, wohingegen die intraduktalen onkozytär-papillären Neoplasien (IOPN) und die intraduktalen tubulopapillären Neoplasien (ITPN) mit weniger aggressiven Subtypen von Pankreaskarzinomen und besserer Prognose assoziiert sind. Daher ist es von größter Bedeutung, diese Läsionen korrekt zu klassifizieren und von anderen nichtduktalen Neoplasien zu differenzieren, wie beispielsweise von neuroendokrinen Tumoren und Azinuszellkarzinomen, welche selten auch ein intraduktales Wachstum aufweisen können. PanIN sind mikroskopische Läsionen mit begrenzter klinischer Signifikanz. Hingegen können alle anderen intraduktalen Neoplasien mittels Bildgebung als zystische Prozesse und/oder solide Tumoren identifiziert werden, wodurch die Indikation für eine mögliche chirurgische Resektion gegeben ist. In dieser Übersichtsarbeit werden die diagnostisch relevanten Aspekte intraduktaler Neoplasien des Pankreas vorgestellt. Diese sind für die Diskussion im Rahmen interdisziplinärer Tumorkonferenzen (Resektion versus watch & wait) sowie zur intraoperativen Entscheidung des Resektionsausmaßes von maßgeblicher Bedeutung.

Autres résumés

Type: Publisher (ger)
Die aktuelle WHO-Klassifikation für gastrointestinale Tumoren (2019) beinhaltet Neuerungen in der Einteilung von intraduktalen Pankreasneoplasien, die auf weiterführenden Erkenntnissen zum genetischen Profil der Tumoren und zum Malignitätspotenzial basieren. Zu dieser Gruppe zählen pankreatische intraepitheliale Neoplasien (PanIN) und intraduktale papillär-muzinöse Neoplasien (IPMN) als Vorläufer des duktalen Adenokarzinoms, wohingegen die intraduktalen onkozytär-papillären Neoplasien (IOPN) und die intraduktalen tubulopapillären Neoplasien (ITPN) mit weniger aggressiven Subtypen von Pankreaskarzinomen und besserer Prognose assoziiert sind. Daher ist es von größter Bedeutung, diese Läsionen korrekt zu klassifizieren und von anderen nichtduktalen Neoplasien zu differenzieren, wie beispielsweise von neuroendokrinen Tumoren und Azinuszellkarzinomen, welche selten auch ein intraduktales Wachstum aufweisen können. PanIN sind mikroskopische Läsionen mit begrenzter klinischer Signifikanz. Hingegen können alle anderen intraduktalen Neoplasien mittels Bildgebung als zystische Prozesse und/oder solide Tumoren identifiziert werden, wodurch die Indikation für eine mögliche chirurgische Resektion gegeben ist. In dieser Übersichtsarbeit werden die diagnostisch relevanten Aspekte intraduktaler Neoplasien des Pankreas vorgestellt. Diese sind für die Diskussion im Rahmen interdisziplinärer Tumorkonferenzen (Resektion versus watch & wait) sowie zur intraoperativen Entscheidung des Resektionsausmaßes von maßgeblicher Bedeutung.

Identifiants

pubmed: 34402978
doi: 10.1007/s00292-021-00966-1
pii: 10.1007/s00292-021-00966-1
doi:

Types de publication

Journal Article Review

Langues

ger

Sous-ensembles de citation

IM

Pagination

472-483

Informations de copyright

© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Références

Adsay NV, Pierson C, Sarkar F et al (2001) Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 25:26–42
pubmed: 11145249 doi: 10.1097/00000478-200101000-00003 pmcid: 11145249
Adsay V, Mino-Kenudson M, Furukawa T et al (2016) Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: recommendations of Verona consensus meeting. Ann Surg 263:162–177
pubmed: 25775066 doi: 10.1097/SLA.0000000000001173 pmcid: 25775066
Amato E, Molin MD, Mafficini A et al (2014) Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233:217–227
pubmed: 24604757 pmcid: 4057302 doi: 10.1002/path.4344
Andea A, Sarkar F, Adsay VN (2003) Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 16:996–1006
pubmed: 14559982 doi: 10.1097/01.MP.0000087422.24733.62 pmcid: 14559982
Bartsch DK, Dietzel K, Bargello M et al (2013) Multiple small “imaging” branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer 12:89–96
pubmed: 23179793 doi: 10.1007/s10689-012-9582-y pmcid: 23179793
Basturk O, Adsay V, Askan G et al (2017) Intraductal tubulopapillary neoplasm of the pancreas: a clinicopathologic and immunohistochemical analysis of 33 cases. Am J Surg Pathol 41:313–325
pubmed: 27984235 pmcid: 5309137 doi: 10.1097/PAS.0000000000000782
Basturk O, Berger MF, Yamaguchi H et al (2017) Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Mod Pathol 30:1760–1772
pubmed: 28776573 doi: 10.1038/modpathol.2017.60 pmcid: 28776573
Basturk O, Chung SM, Hruban RH et al (2016) Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch 469:523–532
pubmed: 27591765 pmcid: 5083199 doi: 10.1007/s00428-016-2014-x
Basturk O, Hong SM, Wood LD et al (2015) A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39:1730–1741
pubmed: 26559377 pmcid: 4646710 doi: 10.1097/PAS.0000000000000533
Basturk O, Tan M, Bhanot U et al (2016) The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol 29:1058–1069
pubmed: 27282351 pmcid: 5524210 doi: 10.1038/modpathol.2016.98
Caravati A, Andrianello S, Pollini T et al (2020) Branch duct intraductal papillary mucinous neoplasms: recommendations for follow-up and surgery. Scand J Surg 109:34–41
pubmed: 32009571 doi: 10.1177/1457496919900414
Chang X, Jiang Y, Li J et al (2014) Intraductal tubular adenomas (pyloric gland-type) of the pancreas: clinicopathologic features are similar to gastric-type intraductal papillary mucinous neoplasms and different from intraductal tubulopapillary neoplasms. Diagn Pathol 9:172
pubmed: 25245835 pmcid: 4180592 doi: 10.1186/s13000-014-0172-1
Chang YR, Park JK, Jang J‑Y et al (2016) Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of 21,745 individuals: large-scale, single-center cohort study. Medicine 95:e5535–e5535
pubmed: 28002329 pmcid: 5181813 doi: 10.1097/MD.0000000000005535
Date K, Ohtsuka T, Nakamura S et al (2018) Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pancreatic ductal adenocarcinoma. Surgery 163:291–299
pubmed: 29221879 doi: 10.1016/j.surg.2017.09.040 pmcid: 29221879
Date K, Okabayashi T, Shima Y et al (2016) Clinicopathological features and surgical outcomes of intraductal tubulopapillary neoplasm of the pancreas: a systematic review. Langenbecks Arch Surg 401:439–447
pubmed: 27001682 doi: 10.1007/s00423-016-1391-6 pmcid: 27001682
Del Chiaro M, Ateeb Z, Hansson MR et al (2017) Survival analysis and risk for progression of intraductal papillary mucinous neoplasia of the pancreas (IPMN) under surveillance: a single-institution experience. Ann Surg Oncol 24:1120–1126
pubmed: 27822633 doi: 10.1245/s10434-016-5661-x pmcid: 27822633
Esposito I, Bauer A, Hoheisel JD et al (2004) Microcystic tubulopapillary carcinoma of the pancreas: a new tumor entity? Virchows Arch 444:447–453
pubmed: 15014986 doi: 10.1007/s00428-004-0984-6 pmcid: 15014986
Esposito I, Haeberle L (2021) Acinar-to-ductal metaplasia. In: van Krieken J (Hrsg) Encyclopedia of pathology. Springer, Cham
Esposito I, Haeberle L (2021) Nonmucinous cystic lesions of the pancreas. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2020-0446-RA
doi: 10.5858/arpa.2020-0446-RA pubmed: 33503226 pmcid: 33503226
Esposito I, Schlitter AM, Sipos B et al (2015) Classification and malignant potential of pancreatic cystic tumors. Pathologe 36:99–112 (quiz 113–114)
pubmed: 25663186 doi: 10.1007/s00292-014-1971-6
Esposito I, Segler A, Steiger K et al (2015) Pathology, genetics and precursors of human and experimental pancreatic neoplasms: an update. Pancreatology 15:598–610
pubmed: 26365060 doi: 10.1016/j.pan.2015.08.007
Esposito I, Seiler C, Bergmann F et al (2007) Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment. Pancreas 35:212–217
pubmed: 17895840 doi: 10.1097/mpa.0b013e31805d0190
European Study Group on Cystic Tumours of the Pancreas (2018) European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67:789–804
doi: 10.1136/gutjnl-2018-316027
Gaujoux S, Brennan MF, Gonen M et al (2011) Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg 212:590–600 (discussion 600–593)
pubmed: 21463795 doi: 10.1016/j.jamcollsurg.2011.01.016
Haeberle L, Schramm M, Goering W et al (2021) Molecular analysis of cyst fluids improves the diagnostic accuracy of pre-operative assessment of pancreatic cystic lesions. Sci Rep 11:2901–2901
pubmed: 33536452 pmcid: 7858638 doi: 10.1038/s41598-021-81065-2
Hata T, Suenaga M, Marchionni L et al (2018) Genome-wide somatic copy number alterations and mutations in high-grade pancreatic intraepithelial neoplasia. Am J Pathol 188:1723–1733
pubmed: 29684357 pmcid: 6024190 doi: 10.1016/j.ajpath.2018.03.012
Heckler M, Brieger L, Heger U et al (2018) Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pancreas. BJS Open 2:13–24
pubmed: 29951625 pmcid: 5989990 doi: 10.1002/bjs5.38
Hong SM, Goggins M, Wolfgang CL et al (2012) Vascular invasion in infiltrating ductal adenocarcinoma of the pancreas can mimic pancreatic intraepithelial neoplasia: a histopathologic study of 209 cases. Am J Surg Pathol 36:235–241
pubmed: 22082604 pmcid: 3261341 doi: 10.1097/PAS.0b013e3182376e36
Hosoda W, Chianchiano P, Griffin JF et al (2017) Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J Pathol 242:16–23
pubmed: 28188630 pmcid: 5553451 doi: 10.1002/path.4884
Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586
pubmed: 11342768 doi: 10.1097/00000478-200105000-00003 pmcid: 11342768
Hruban RH, Takaori K, Klimstra DS et al (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977–987
pubmed: 15252303 doi: 10.1097/01.pas.0000126675.59108.80 pmcid: 15252303
Hutchings D, Waters KM, Weiss MJ et al (2018) Cancerization of the pancreatic ducts: demonstration of a common and under-recognized process using immunolabeling of paired duct lesions and invasive pancreatic ductal adenocarcinoma for p53 and Smad4 expression. Am J Surg Pathol 42:1556–1561
pubmed: 30212393 pmcid: 6266304 doi: 10.1097/PAS.0000000000001148
Ideno N, Ohtsuka T, Kono H et al (2013) Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258:141–151
pubmed: 23532108 doi: 10.1097/SLA.0b013e31828cd008
Kanda M, Matthaei H, Wu J et al (2012) Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142:730–733.e9
pubmed: 22226782 doi: 10.1053/j.gastro.2011.12.042
Kim H, Ro JY (2018) Intraductal tubulopapillary neoplasm of the pancreas: an overview. Arch Pathol Lab Med 142:420–423
pubmed: 29494224 doi: 10.5858/arpa.2016-0405-RSR2
Kleeff J, Michalski C, Kong B et al (2015) Surgery for cystic pancreatic lesions in the post-Sendai era: a single institution experience. Hpb Surg 2015:847837
pubmed: 25873753 pmcid: 4383461 doi: 10.1155/2015/847837
Kloppel G, Basturk O, Schlitter AM et al (2014) Intraductal neoplasms of the pancreas. Semin Diagn Pathol 31:452–466
pubmed: 25282472 doi: 10.1053/j.semdp.2014.08.005
Konstantinidis IT, Vinuela EF, Tang LH et al (2013) Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance? Ann Surg Oncol 20:3643–3647
pubmed: 23748606 doi: 10.1245/s10434-013-3042-2
Kuan LL, Dennison AR, Garcea G (2020) Intraductal tubulopapillary neoplasm of the pancreas and bile duct: a review. Pancreas 49:498–502
pubmed: 32282762 doi: 10.1097/MPA.0000000000001518
Lee KS, Sekhar A, Rofsky NM et al (2010) Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 105:2079–2084
pubmed: 20354507 doi: 10.1038/ajg.2010.122 pmcid: 20354507
Lim J, Allen PJ (2019) The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made? Updates Surg 71:209–216
pubmed: 31175628 doi: 10.1007/s13304-019-00661-0 pmcid: 31175628
Lüttges J, Galehdari H, Bröcker V et al (2001) Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 158:1677–1683
pubmed: 11337365 pmcid: 1891939 doi: 10.1016/S0002-9440(10)64123-5
Lüttges J, Reinecke-Lüthge A, Möllmann B et al (1999) Duct changes and K‑ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch 435:461–468
pubmed: 10592048 doi: 10.1007/s004280050428 pmcid: 10592048
Marchegiani G, Mino-Kenudson M, Ferrone CR et al (2015) Patterns of recurrence after resection of IPMN: who, when, and how? Ann Surg 262:1108–1114
pubmed: 25793719 doi: 10.1097/SLA.0000000000001008 pmcid: 25793719
Marchegiani G, Mino-Kenudson M, Ferrone CR et al (2015) Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg 220:839–844
pubmed: 25840549 doi: 10.1016/j.jamcollsurg.2015.01.051 pmcid: 25840549
Marchegiani G, Mino-Kenudson M, Sahora K et al (2015) IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg 261:976–983
pubmed: 24979607 doi: 10.1097/SLA.0000000000000813 pmcid: 24979607
Matsuda R, Miyasaka Y, Ohishi Y et al (2020) Concomitant intraductal papillary mucinous neoplasm in pancreatic ductal adenocarcinoma is an independent predictive factor for the occurrence of new cancer in the remnant pancreas. Ann Surg 271:941–948
pubmed: 30308608 doi: 10.1097/SLA.0000000000003060 pmcid: 30308608
Matthaei H, Hong SM, Mayo SC et al (2011) Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Ann Surg Oncol 18:3493–3499
pubmed: 21537863 pmcid: 3166423 doi: 10.1245/s10434-011-1745-9
Mattiolo P, Hong SM, Paolino G et al (2020) CD117 is a specific marker of intraductal papillary mucinous neoplasms (IPMN) of the pancreas, oncocytic subtype. Int J Mol Sci 21:5794
pmcid: 7461050 doi: 10.3390/ijms21165794
Mino-Kenudson M, Fernandez-Del Castillo C, Baba Y et al (2011) Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60:1712–1720
pubmed: 21508421 doi: 10.1136/gut.2010.232272
Oyama H, Tada M, Takagi K et al (2020) Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms. Gastroenterology 158:226–237.e5
pubmed: 31473224 doi: 10.1053/j.gastro.2019.08.032
Pea A, Yu J, Rezaee N et al (2017) Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg 266:133–141
pubmed: 27433916 doi: 10.1097/SLA.0000000000001817
Pergolini I, Sahora K, Ferrone CR et al (2017) Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral center. Gastroenterology 153:1284–1294.e1
pubmed: 28739282 doi: 10.1053/j.gastro.2017.07.019
Reichert M, Blume K, Kleger A et al (2016) Developmental pathways direct pancreatic cancer initiation from its cellular origin. Stem Cells Int 2016:9298535
pubmed: 26681957 doi: 10.1155/2016/9298535
Sahora K, Fernández-Del Castillo C, Dong F et al (2014) Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery 156:611–621
pubmed: 25081232 doi: 10.1016/j.surg.2014.04.023
Salvia R, Fernández-Del Castillo C, Bassi C et al (2004) Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 239:678–685 (discussion 685–677)
pubmed: 15082972 pmcid: 1356276 doi: 10.1097/01.sla.0000124386.54496.15
Singh M, Maitra A (2007) Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 7:9–19
pubmed: 17449961 doi: 10.1159/000101873
Singhi AD, Mcgrath K, Brand RE et al (2017) Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut 67:2131–2141
pubmed: 28970292 doi: 10.1136/gutjnl-2016-313586
Singhi AD, Wood LD, Parks E et al (2020) Recurrent rearrangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct. Gastroenterology 158:573–582.e2
pubmed: 31678302 doi: 10.1053/j.gastro.2019.10.028 pmcid: 31678302
Sipos B, Frank S, Gress T et al (2009) Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 9:45–54
pubmed: 19077454 doi: 10.1159/000178874
Tan MC, Basturk O, Brannon AR et al (2015) GNAS and KRAS mutations define separate progression pathways in intraductal papillary mucinous neoplasm-associated carcinoma. J Am Coll Surg 220:845–854.e1
pubmed: 25840541 pmcid: 4409519 doi: 10.1016/j.jamcollsurg.2014.11.029
Tanaka M, Chari S, Adsay V et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32
pubmed: 16327281 doi: 10.1159/000090023
Valsangkar NP, Morales-Oyarvide V, Thayer SP et al (2012) 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 152:S4–S12
pubmed: 22770958 doi: 10.1016/j.surg.2012.05.033
Vanella G, Crippa S, Archibugi L et al (2018) Meta-analysis of mortality in patients with high-risk intraductal papillary mucinous neoplasms under observation. Br J Surg 105:328–338
pubmed: 29405253 doi: 10.1002/bjs.10768
Wang T, Askan G, Adsay V et al (2019) Intraductal oncocytic papillary neoplasms: clinical-pathologic characterization of 24 cases, with an emphasis on associated invasive carcinomas. Am J Surg Pathol 43:656–661
pubmed: 30986801 pmcid: 6467507 doi: 10.1097/PAS.0000000000001226
WHO Classification of Tumours Editorial Board (2019) Digestive system tumours. IARC, Lyon
Yamaguchi A, Hamada T, Wada K et al (2021) A case of intraductal tubulopapillary neoplasm of the pancreas in a branch duct: a rare case report and literature review. BMC Gastroenterol 21:162
pubmed: 33849435 pmcid: 8045350 doi: 10.1186/s12876-021-01744-2
Yamaguchi H, Shimizu M, Ban S et al (2009) Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 33:1164–1172
pubmed: 19440145 doi: 10.1097/PAS.0b013e3181a162e5
Yamaguchi K, Kanemitsu S, Hatori T et al (2011) Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40:571–580
pubmed: 21499212 doi: 10.1097/MPA.0b013e318215010c
Yamasaki S, Suda K, Nobukawa B et al (2002) Intraductal spread of pancreatic cancer. Clinicopathologic study of 54 pancreatectomized patients. Pancreatology 2:407–412
pubmed: 12138230 doi: 10.1159/000065089 pmcid: 12138230

Auteurs

Irene Esposito (I)

Institut für Pathologie, Heinrich-Heine-Universität und Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland. irene.esposito@med.uni-duesseldorf.de.

Lena Häberle (L)

Institut für Pathologie, Heinrich-Heine-Universität und Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Aslihan Yavas (A)

Institut für Pathologie, Heinrich-Heine-Universität und Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Anne Kraft (A)

Institut für Pathologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.

Matthias M Gaida (MM)

Institut für Pathologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.
Forschungszentrum Immuntherapie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.
Joint Unit Immunpathologie, Translationale Onkologie, Institut für Pathologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH